Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Glucodynamics of LY900014 in Healthy Chinese Subjects
NCT04049123Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2019
- Primary completion
- Oct 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of insulin lispro in diabetes mellitus (DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Insulin Lispro Area Under the Serum Concentration Versus Time Curve From Time Zero to 10 Hours Postdose. Started Nov 2019; status: completed.
02
Drugs
insulin lispro
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT04049123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04049123.